Charles River Laboratories | CRL - Gross Profit On Sales



Charles River Laboratories reported $367.77M in Gross Profit on Sales for its fiscal quarter ending in September of 2024.

Gross Profit On Sales Change Date
Agilent USD 855M 0 Jul/2024
Align Technology USD 681.77M 40.86M Sep/2024
Bio-Rad Laboratories USD 355.9M 183K Sep/2024
Bruker USD 418.8M 34.2M Sep/2024
Cardinal Health USD 1.9B 20M Sep/2024
Catalent USD 181M 203M Sep/2024
Charles River Laboratories USD 367.77M 36K Sep/2024
Cigna USD 57.06B 50.59B Sep/2024
CVS Health USD 12.56B 431M Sep/2024
Danaher USD 3.4B 27M Sep/2024
Dentsply International USD 495M 16M Sep/2024
Elevance Health 12.16B 10.85B Sep/2024
Galapagos EUR 59.83M 72.13M Sep/2024
Hologic USD 607.5M 10.5M Sep/2024
Humana 480M 29.9M Sep/2024
Illumina USD 745M 24M Sep/2024
Incyte USD 106.46M 277.72M Sep/2024
IQVIA Holdings USD 915M 411M Sep/2024
Laboratory Of America USD 904.4M 22M Sep/2024
Lonza CHF 1.12B 276M Jun/2024
McKesson USD 3.25B 6M Sep/2024
Merck EUR 3.14B 89M Sep/2024
Mettler Toledo International USD 572.47M 6.8M Sep/2024
Novartis USD 9.94B 239M Sep/2024
Pfizer USD 12.44B 1.92B Sep/2024
Quest Diagnostics USD 816M 12M Sep/2024
Revvity USD 384.82M 690K Sep/2024
Thermo Fisher Scientific USD 4.42B 71M Sep/2024
United Therapeutics USD 665.8M 28.7M Sep/2024
UnitedHealth 23.03B 972M Sep/2024
Walgreens Boots Alliance USD 6.4B 56M Aug/2024
Waters USD 438.65M 18.37M Sep/2024
West Pharmaceutical Services USD 264.7M 34.7M Sep/2024